medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


The NEW ENGLAND JOURNAL of MEDICINE

Please review the Supplemental Files folder to review documents not compiled in the PDF.

# Interferon Beta-1α ring prophylaxis to reduce household transmission of SARS-CoV-2

| | |
|---|---|
| Journal: | *New England Journal of Medicine* |
| Manuscript ID | Draft |
| Article Type: | Original Article |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Castro-Rodriguez, Jose; Pontifical Catholic University of Chile, Pediatrics<br>Fish, Eleanor; Toronto General Research Institute, University Health Network; University of Toronto, Immunology<br>Kollmann, Tobias; Telethon Kids Institute; Perth Children's Hospital, Infectious Diseases<br>Iturriaga, Carolina; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology<br>Karpievitch, Yulia; Telethon Kids Institute; The University of Western Australia, School of Biomedical Sciences<br>Shannon, Casey; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation<br>Chen, Virginia; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation<br>Balshaw, Robert; University of Manitoba College of Medicine, George and Fay Yee Centre for Healthcare Innovation<br>Ben Othman, Rym; Telethon Kids Institute<br>Montgomery, Samuel; Telethon Kids Institute,<br>Aniba, Radhouana; Telethon Kids Institute<br>Ho, Joseph; Telethon Kids Institute<br>Gidi-Yunge, Fancisca; Pontifical Catholic University of Chile, School of Dentistry<br>Hartnell, Lucy; Telethon Kids Institute<br>Perez-Mateluna, Guillermo; Pontifical Catholic University of Chile, Department of Pediatric Infectious Diseases and Immunology<br>Urzúa, Marcela; Pontifical Catholic University of Chile, Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina<br>Tebbutt, Scott; UBC; The University of British Columbia Centre for Heart Lung Innovation<br>Garcia-Huidobro, Diego; Pontifical Catholic University of Chile, Department of Family Medicine; University of Minnesota Twin Cities, Department of Family Medicine and Community Health<br>Perret, Cecilia; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology<br>Borzutzky, Arturo; Pontificia Universidad Católica de Chile, Pediatric Infectious Diseases and Immunology<br>Stick, Stephen; Telethon Kids Institute, Wal-yan Respiratory Research Centre; The University of Western Australia, Centre for Child Health Research; Perth Children's Hospital, Respiratory and Sleep Medicine |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






| | |
|---|---|
| Abstract: | Background<br>Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFNß-1☐ could reduce SARS-CoV-2 household transmission.<br>Methods<br>A household cluster randomized controlled study of IFNß-1☐ administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years compared to standard care, was conducted. Following randomization participants received IFNß-1☐ on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household contacts.<br>Results<br>In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFNß-1☐ and 565 to standard care. Based on intention to treat and per protocol analyses, IFNß-1☐ treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFNß-1☐ reduced household transmission.<br>Conclusion<br>Ring prophylaxis with IFNß-1☐ reduces the probability of SARS-CoV-2 transmission within a household. |
| | |


SCHOLARONE™
Manuscripts

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


# Interferon Beta-1α ring prophylaxis to reduce household transmission of SARS-CoV-2

**Authors**

José A. Castro-Rodriguez, PhD
Pontifical Catholic University of Chile

Eleanor N. Fish PhD
University of Toronto

Tobi Kollmann PhD
Telethon Kids Institute

Carolina Iturriaga, RN
Pontifical Catholic University of Chile

Yuliya Karpievitch PhD
Telethon Kids Institute

Casey Shannon BSc
Prevention of Organ Failure (PROOF) Centre of Excellence

Virginia Chen BSc
Prevention of Organ Failure (PROOF) Centre of Excellence

Robert Balshaw PhD
Centre for Healthcare Innovation, University of Manitoba

Samuel Montgomery PhD
Telethon Kids Institute

Joseph Ho, MSc
Telethon Kids Institute

Rym Ben Othman, PhD
Telethon Kids Institute

Radhouana Aniba, PhD
Telethon Kids Institute

Francisca Gidi-Yunge, DDS
Pontifical Catholic University of Chile

Lucy Hartnell, MSc
Telethon Kids Institute

Guillermo Pérez-Mateluna, Biotech
Pontifical Catholic University of Chile

Marcela Urzúa, RN
Pontifical Catholic University of Chile

Scott Tebbutt, PhD
Prevention of Organ Failure (PROOF) Centre of Excellence

Diego García-Huidobro, PhD
Pontifical Catholic University of Chile

Cecilia Perret, MD
Pontifical Catholic University of Chile

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Arturo Borzutzky, MD
Pontifical Catholic University of Chile

Stephen M. Stick, PhD
Telethon Kids Institute

**Corresponding author:** Professor Stephen Stick
stephen.stick@health.wa.gov.au

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


**Abstract (words 250)**

Background

Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFNß-1α could reduce SARS-CoV-2 household transmission.

Methods

A household cluster randomized controlled study of IFNß-1α administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years compared to standard care, was conducted. Following randomization participants received IFNß-1α on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household contacts.

Results

In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFNß-1α and 565 to standard care. Based on intention to treat and per protocol analyses, IFNß-1α treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFNß-1α reduced household transmission.

Confidential. For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Conclusion

Ring prophylaxis with IFNß-1α reduces the probability of SARS-CoV-2 transmission within a household.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


**Introduction (Words 3284)**

The SARS-CoV-2 pandemic has claimed over six million lives. Despite the rapid development and deployment of vaccines in many countries, the number of new cases worldwide still exceeds 500,000 daily (https://covid19.who.int). With each wave of the pandemic, health systems have been challenged and the likelihood of emergence of mutant strains of the virus remains. Mutated strains may be more transmissible [1,2], cause more severe disease than the original pandemic strain of SARS-CoV-2 [3] and have the potential to evade available vaccines [4,5]. Whilst widespread vaccination has had success limiting the trajectory of the pandemic, the emergence of the omicron variants demonstrated that even with mutations that appear to cause less severe disease [6] , high transmission despite immunization could still result in significant pressures on health services [7].

The solution to halting any pandemic is ending community transmission. During the current pandemic, measures such as healthy hygiene, self-isolation when sick, physical-distancing and use of facemasks have all been effective [8]. Moreover, expedited public health responses such as extensive contact-tracing, testing for infection and community lockdowns have all been effective methods to curb transmission [9]. International and local border closures plus strict quarantine measures have reduced community transmission to zero for periods in countries such as Australia and New Zealand [10,11]. However, in these countries and elsewhere, as restrictions are relaxed, localized outbreaks have occurred [12] that have required rapid, community-wide responses to again supress transmission. Importantly, these community constraints cause unprecedented civil disruption and come at enormous economic [13,14]and social costs [15,16].

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Since the evolution of dominant SARS-CoV-2 virus cannot be easily predicted [17], there remains a need to identify interventions that can be rapidly deployed should highly pathogenic strains emerge despite high levels of community immunization. Furthermore, preparations for the next pandemic must include strategies to limit the potential for infection and transmission on first contact with pathogenic respiratory viruses.

One of the many therapeutic approaches investigated that appeared clinically useful early in the course of the pandemic was treatment with type 1 interferons (IFNs). Randomized, controlled studies suggest that IFNs offer clinical benefits in moderate [18] and severe disease [19,20] }, reduce the duration of viral shedding [21] and prevent infection in front-line hospital workers [22]. Nonetheless, IFNs are not generally recommended for treatment of proven cases of Covid-19 [23].

Since IFNs are sentinel innate immune signalling molecules produced early after first contact with viral pathogens [24-26], we postulated that prophylactic IFN treatment might reduce susceptibility to infection of uninfected contacts of individuals with SARS-CoV-2 infection. Such post-exposure prophylaxis could provide non-specific, antiviral protection to curb episodic viral outbreaks [27], help suppress community transmission, even in vaccinated populations, and therefore reduce the risk of emergence of dangerous mutations [4,28].

We therefore undertook a cluster, randomized, controlled study of sub-cutaneous pegylated IFNß-1$\alpha$ (Plegridy. Biogen Inc, Cambridge MA) administration to determine whether IFNß-1$\alpha$ therapy given to index cases and household contacts can reduce transmission of SARS-CoV-2.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


## Methods

The Containing Coronavirus Disease-19 (ConCorD-19) trial was a prospective, cluster, randomized trial of subcutaneous (sc) administration of pegylated IFNß-1α (Plegridy, Biogen Inc, Switzerland) versus standard care (control) [29]. Each household of an index case was randomized to either the IFNß-1α treatment or the standard care control arm. The study was approved by the Institutional Review Board of the Pontificia Universidad Católica de Chile and was registered with clinicaltrials.gov (NCT04552379). All participants provided written informed consent.

*Trial population*

Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19 clinics and emergency room visits in Santiago, Chile. Households were contacted by telephone to determine eligibility prior to enrolment. Individuals aged between 18 and 80 years who met inclusion and exclusion criteria were deemed as 'eligible' contacts with households only included if there was at least one eligible contact [29]. Enrolment and the first doses of IFNß-1α - if in the intervention arm- had to be within 72 hours of the positive identification of SARS-CoV-2 by polymerase chain reaction (PCR) in index cases. A household was excluded if the index case had been in complete self-quarantine from other household members during the 48 hours prior to the diagnosis of SARS-CoV-2 infection [29]. Household characteristics were captured consistent with recommendations of the World Health Organization for assessing household transmission [30]. All participants implemented quarantine measures as mandated by local authorities and maintained a daily symptom diary which was collected and reviewed at each study visit by the study team (see online supplementary material). At any time during the trial, if a contact participant developed symptoms suggestive of COVID-19, a nasopharyngeal swab was taken by a member of a mobile health team for virus PCR testing in an

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


accredited SARS-CoV-2 diagnostic laboratory. Index cases were instructed to remain in isolation / quarantine for 11 days from onset of symptoms or, if asymptomatic, 11 days from the sample collection date that resulted in the COVID-19 diagnosis. Household contacts remained in isolation / quarantine for 11 days from date of the sample resulting in the diagnosis of the index case or of a newly diagnosed household member as per recommendations/rulings by local authorities.

*Intervention*

A mobile health team conducted home visits of all participant households on study days 1 (enrolment), 6, 11, 16 and 29. Index cases and eligible household contacts in the IFNß-1α arm received three subcutaneous doses of pegylated IFNß-1α (125µg/0.5ml x 0.5ml) on study days 1, 6 and 11. Ineligible contacts in the IFNß-1α arm, as well as index cases and all household contacts in the SOC arm, received standard care. All participating households received information regarding hygiene, isolation, social distancing and wearing of facemasks as per public health advice at the time of enrolment. The IFNß-1α injection was given by a trained member of a mobile health team and participants were recommended to take paracetamol (1000mg, 6 hourly) commencing at the same time as the IFNß-1α for up to twenty-four hours, in order to mitigate predictable flu-like symptoms [31].

*Outcomes*

The primary outcomes were (i) the proportion of index cases shedding SARS-CoV-2 at study day 11 in the IFNß-1α compared to control arm and (ii) the proportion of household contacts shedding SARS-CoV-2 at day 11, in the IFNß-1α compared to the control arm. Secondary and exploratory outcomes are listed in Supplementary Methods (Supplementary Table 1). Shedding was determined by the

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


presence of SARS-CoV-2 by PCR in saliva collected on days 1, 6, 11, 16, 21, and 29 (see Supplementary Methods). A SARS-CoV-2 PCR Ct value ≥40 was considered negative. Viral load was estimated from the Ct value using a standard algorithm (Supplementary Figure 1

*Biospecimen collections*

The full schedule of biospecimen collection is provided in the supplementary methods (Supplementary Tables 2 and 3. All consenting, non-eligible household contacts also provided biospecimens according to the schedule collection for non-eligible household contacts.

*Adverse events*

These were classified in accordance with Good Clinical Practice [32], as non-serious or serious and as related or unrelated to the trial medication.

*Statistical considerations*

The study was designed at the start of the pandemic and there were few data to guide sample size calculations. We therefore planned both frequentist inference and Bayesian analyses based on assumptions from the available data.

Households were randomized as individual clusters using a minimization technique (biased coin, P=0.7) in order to achieve balance between treatment arms, stratified by the number of people within the household [33].

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Sample size calculations assumed, $\alpha$=0.025 and power 90%, a zero correlation between outcome measures and that the household-wise, type 1 error rate would be below 0.05 and power above 80%. The estimated average household size was 4, based on census data [34].

Primary outcomes:

(i) SARS-CoV-2 shedding at study day 11 by index cases: Data from Wuhan suggested that the proportion of untreated index cases still shedding virus on study day 11 would be ~85% [35]. Based on a two tailed Fisher's exact test, a sample size of 278 index cases (139 per arm) would have 90% power to detect a difference in the proportion of individuals shedding virus at study day 11, if the proportion in the IFNß-1$\alpha$ arm was 65%.

(ii) SARS-CoV-2 shedding at study day 11 by household contacts: We estimated the secondary infection rate (transmission within the household) where there is an untreated index case would be 28% [36,37]. Based on a stratified Cochran-Mantel-Haenszel test (two-tailed with intra-class correlation of 0.15), we estimated that a sample of 278 households (834 eligible household contacts) would have >90% power, at alpha 0.025, to detect an odds ratio of 0.5 for a reduction in transmission to a treated household contact.

Based on these assumptions and estimates, we aimed to recruit 310 households (allowing for a 10% drop-out rate) and 930 eligible household contacts.

We undertook 3 separate sets of analyses:

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


(A) Standard frequentist analyses based on the primary outcomes as stated in the protocol and described in the Statistical Analysis Plan (available online) and included intention to treat and per protocol approaches .

(B) Exploratory frequentist analyses based on a modified dataset that accounted for biological implausibility and effects that might only be associated with active treatment (Figure 1 and Supplementary Table 1 for further explanations).

Both frequentist analyses fitted linear mixed effects models using lme4 [38] (see Statistical Analysis Plan).

(C) Exploratory Bayesian analyses using the same dataset as the exploratory frequentist analysis. Detailed methods are provided in the supplementary methods. Briefly, a generalized linear model with mixed effects was developed to estimate the probability of infection that is influenced by explanatory variables for each contact case. A stan_glmer with binomial logit function in rstanarm R package was used [39,40].

The frequentist approach allowed us to estimate the effects of IFNß-1α treatment on the risk of an *individual* becoming infected. Whereas the Bayesian analysis allowed us to determine whether the ring prophylaxis strategy using IFNß-1α reduces the probability of transmission within the household of an infected index case.

With regard to the filtered datasets, we observed, after locking the database, that a number of index cases had negative PCR results on the day of recruitment despite a previous positive diagnostic PCR test. In the exploratory analyses we therefore excluded households where the index case was unlikely to transmit virus because they were not shedding virus on days 1 and day 6 of the study. We

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


also excluded households where an eligible contact was already positive at recruitment and there were no other eligible negative cases in the household. We refer to the modified dataset as the population "at risk". We used the population at risk data to better understand the effects of IFNß-1α treatment on transmission of virus within households.

When undertaking these exploratory analyses, we considered effects during two time periods. Days 1-11 (Period 1) i.e., the treatment and isolation period when eligible contacts in the IFNß-1α arm were likely to have elevated IFN levels based on the known pharmacokinetics of pegylated IFNß-1α and days 12-29 (Period 2) the post-treatment and isolation period when biological effects of pegylated IFNß-1α were likely to be waning in treated individuals. Although samples were not obtained on days 12-15, we assumed that anyone who became infected during this period would likely still to have a positive PCR on day 16.

**Results**

Recruitment, participation, and completion data are shown in Figure 1. Participant demographic and basic household characteristics data are shown in Table 1.

Between December 2020 and May 2021, three-hundred and forty-one households were enrolled and randomized, of which 137 (IFNß-1α arm) and 151 (control arm) completed the study. Of the 1172 individuals randomized (IFNß-1α arm = 607; Controls = 565), 53 individuals withdrew from the study, of which 15 were index cases; 35 (14 index cases) in the IFNß-1α arm and 18 (1 index case) in the control arm. The reasons for withdrawal are summarized in the supplementary results (Supplementary Table 4). One index case withdrew before being allocated to a treatment arm.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Eighty-two households where the index case had a negative salivary PCR on Day 1 and 6, or where there were no eligible contacts who tested negative at recruitment, were excluded from the exploratory analyses. The remaining households were considered as the 'at risk' population. (Figure 1).

*(a) Primary analyses*

The outcomes for the intention to treat (ITT) and per protocol (PP) frequentist analyses were similar (Supplementary Results). There was no effect of IFNβ-1α treatment on duration of viral shedding in those treated (index cases or infected contacts) vs. controls (IC-INF: treatment OR = 0.979, 95%CI = 0.647 to 1.479); IC-ITT: treatment OR = 1.106, 95%CI = 0.657 to 1.863); IC-PP: treatment OR = 1.062, 95%CI = 0.622 to 1.810); Figure 2A). The observed reduction in transmission to household contacts associated with IFNbeta-1alpha by day 11 was not signif icant (EHC-ITT: treatment OR = 0.582, 95%CI = 0.271 to 1.247; HC: treatment OR = 0.577, 95%CI = 0.287 to 1.160; EHC-PP: treatment OR = 0.589, 95%CI = 0.272to 1.276; Figure 2B). Vaccination status did not affect these outcomes (Supplementary results).

*(b) Exploratory frequentist analysis of 'At Risk Population*.'

Of the at risk population, 33/164 (20%) in the IFNß-1α arm became infected by day 29 of the study compared to 37/142 (26%) in the control arm (relative risk reduction in the IFN arm = 23%). The majority of the risk reduction occurred during the active treatment phase of the study (days 1 to 11). Treatment with IFNß-1α was associated with a significant reduction in the odds of a positive saliva PCR for all household contacts compared to standard of care on Day 11 (p = 0.033; OR = 0.550, 95% CI

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


= 0.364 to 0.989). The treatment effect was not significant in the second period (days 12-29) was not significant (OR = 0.968, 95% CI = 0.405 to 2.840) (Figure 2C)

*(c) Exploratory Bayesian analysis:*

Overall, there was a 95% probability of infection reduction within a household by IFNß-1α treatment and the credible interval for the reduction in transmission probability was in the order of 0.9 to 15.9%. During the active treatment period (days 1-11), there was a significant reduction in the odds of transmission (Bayesian analysis (OR = 0.32, 95% Credible Interval = 0.11 to 0.83). In contrast, in Period 2 (day 12-29), the 95% credible interval of *Beta* coefficients for the treatment group includes zero and therefore treatment was not effective in this period (Figure 2C, Supplementary Figure 2). The effect of IFNß-1α on transmission was independent of household size (Supplementary Figure 3)

To determine the effect of IFNß-1α treatment on viral shedding in those who became infected, we examined the viral load trajectories in household contacts who became PCR positive after day 1. We did not observe any difference in viral load trajectory in those treated with IFNß-1α compared to controls (Figure 3A). Furthermore, there was no difference in peak viral load between treated household contacts and controls who became infected (Figure 3B).

There were fifty-eight serious adverse events in index cases, twenty-seven hospitalizations due to COVID-19 (25 in the treatment and 32 in the control arm) and was one death in the standard care arm due to COVID-19 in an individual with significant co-morbidities. Twenty-six household contacts of index cases were hospitalized, 10 in the treatment arm and 16 in the control arm, the difference was not statistically significant.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


**Discussion**

This prospective, household cluster randomized, ring prophylaxis trial demonstrated that pegylated IFNß-1α may reduce household transmission of SARS-CoV-19. Pegylated IFNß-1α is an FDA approved therapy for hepatitis C and multiple sclerosis for which the pharmacokinetics and safety profile are well-characterized [41]. The use of this formulation allowed us to predict the likely duration of activity of the three-dose regimen in order to cover the period of peak transmissibility of the virus. Using a mobile medical team to administer doses at home optimized adherence to therapy and allowed reasons for non-adherence and withdrawal to be accurately documented.

Although the intention to treat and per protocol analyses failed to demonstrate a significant effect on primary outcomes, these analyses failed to account for index cases not shedding virus at randomization nor an absence of eligible contacts within a household. Using biologically plausible filters to define an at-risk population provided a better understanding of the effects of IFNß-1α than intention to treat or per protocol analyses. These exploratory analyses that took account of the likelihood that transmission could occur within a household provided a pragmatic assessment of the effects of IFNß-1α therapy when given to household contacts as prophylaxis.

The frequentist analysis of the at-risk populations indicated that *individuals* treated with IFN were less likely to become infected than untreated individuals when exposed to virus with a relative risk reduction of 23%. The Bayesian analysis revealed that the probability was 95% that transmission was reduced in *households* randomized to IFNß-1α therapy. This effect of IFNß-1α on household transmission was only significant during the active treatment period. This highlights the physiological

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


importance of IFNß-1α as a sentinel molecule [24] and provides further evidence for post-exposure prophylaxis with IFNß-1α as an antiviral strategy.

To our knowledge, only one previous study assessed ring prophylaxis in COVID-19. Labhardt et al observed that a combination of lopinavir/ritonavir for 5 days as post-exposure prophylaxis was not effective at preventing infection in close contacts of index cases [42].

The overall viral load trajectory we observed was very similar to that observed in a laboratory human challenge experiment using wild-type SARS-CoV-2 virus in healthy volunteers [43]. Treatment with IFNß-1α had no effect on viral load trajectory; therefore, reduced viral shedding by infected individuals is unlikely to explain the protective effect on household transmission of IFNß-1α treatment that we report . Given that treatment affected the probability of transmission only in the active treatment phase and appears unrelated to viral load, we speculate that the observed effects of IFNß-1α were direct through protection of the at-risk, exposed individual rather than indirectly though effects on the index case. The ConCoRD-19 biorepository will allow further examination of the mechanisms of action of IFNß-1α on resistance to infection.

The study was undertaken prior to the emergence of the omicron strain of virus. We calculated the sample size based upon known household transmission characteristics of the alpha strain which was the dominant strain of the virus early in the pandemic. Simple hygiene measures and quarantine of affected individuals within households could have contributed to lower rates of transmission than expected. Together with a smaller number of eligible household contacts than anticipated from census data, these factors may have reduced the power of the study for the primary outcomes. The

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


effect size observed in this study could be greater for variants with higher transmissibility such as the Omicron strains that are now the dominant worldwide.

Nonetheless, the beneficial biological effect of IFNß-1α treatment was evident in the at-risk population and therefore, post-exposure or ring prophylaxis with IFNß-1α warrants further investigation, particularly if additional virulent strains of SARS-CoV-2 emerge and for future pandemic virus preparedness.

In summary, although intention to treat and per protocol analyses failed to demonstrate significant effects on primary outcomes, in a biologically defined, at risk population, the relative risk of infection for an individual treated with pegylated IFNß-1α was reduced by 23.0%. Moreover, this is the first study to demonstrate ring prophylaxis with pegylated IFNß-1α significantly reduces the probability of household transmission of SARS-CoV-2. The effect of pegylated IFNß-1α was most obvious during the active phase of treatment. In situations where there is emergence of a highly pathogenic and transmissible mutant strain of SARS-CoV-2 despite high vaccination rates, or when there is a new viral pandemic, IFNß-1α ring prophylaxis could be considered to reduce transmission in households or amongst critical workers and vulnerable communities. Ring prophylaxis with therapies that can interrupt transmission appears to be an effective strategy for highly contagious respiratory viruses.

**Funding.**
Biogen PTY Ltd. Supply of interferon as "Plegridy".
The study was substantially funded by BHP Holdings Pty Ltd

**Authorship**
Authors, Castro-Rodriguez; Fish; Kollmann; Iturriaga, Karpievitch and Shannon contributed equally to the conduct of the study and manuscript as first authors.

Authors, Tebbutt, Diego García-Huidobro, Perret, Borzutsky and Stick contributed equally to the conduct of the study and manuscript as senior authors.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


**Acknowledgements**

Matthew Cooper (Telethon Kids Institute). Advice regarding protocol and establishment of randomization schedule.

Alexia Foti (Telethon Kids Institute). Collating, reviewing, and editing documents.

Zsuzsanna Hollander (PROOF Centre, Vancouver). Statistical advice and statistical analysis plan review.

Nat Eiffler (Telethon Kids Institute). Project management, protocol development, data management.

Jessica Meyer (University of Rochester). Assisting collation and formatting of tables and figures.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


## References

1. Alizon S, Haim-Boukobza S, Foulongne V, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Euro Surveill 2021;26(28). DOI: 10.2807/1560-7917.ES.2021.26.28.2100573.

2. Mishra S, Mindermann S, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine 2021;39:101064. DOI: 10.1016/j.eclinm.2021.101064.

3. Twohig K, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases 2021. DOI: 10.1016/ S1473-3099(21)00475-8.

4. Winger A, Caspari T. The Spike of Concern-The Novel Variants of SARS-CoV-2. Viruses 2021;13(6). DOI: 10.3390/v13061002.

5. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. medRxiv 2021.

6. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022;399(10332):1303-1312. DOI: 10.1016/S0140-6736(22)00462-7.

7. Le Rutte E, Shattock A, Chitnis N, Kelly. SL, Penny M. Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden. medRXiv. Online server: Cold Spring Harbor Laboratory; 2021.

8. Centers for Disease Control and Prevention. Implementation of Mitigation Strategies for Communities with Local COVID-19 Transmission. CDC. May 23 2021.

9. Milne GJ, Xie S, Poklepovich D, O'Halloran D, Yap M, Whyatt D. A modelling analysis of the effectiveness of second wave COVID-19 response strategies in Australia. Sci Rep 2021;11(1):11958. DOI: 10.1038/s41598-021-91418-6.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


10. National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 38 Reporting period ending 28 March 2021. Commun Dis Intell (2018) 2021;45. DOI: 10.33321/cdi.2021.45.19.

11. Houvessou GM, Souza TP, Silveira MFD. Lockdown-type containment measures for COVID-19 prevention and control: a descriptive ecological study with data from South Africa, Germany, Brazil, Spain, United States, Italy and New Zealand, February - August 2020. Epidemiol Serv Saude 2021;30(1):e2020513. DOI: 10.1590/S1679-49742021000100025.

12. Conway SR, Lazarski CA, Field NE, et al. SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. Front Immunol 2021;12:793197. DOI: 10.3389/fimmu.2021.793197.

13. Cutler DM, Summers LH. The COVID-19 Pandemic and the $16 Trillion Virus. JAMA 2020;324(15):1495-1496. DOI: 10.1001/jama.2020.19759.

14. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand out in high-frequency shipping data. PLoS One 2021;16(4):e0248818. DOI: 10.1371/journal.pone.0248818.

15. Chemen S, Gopalla YN. Lived experiences of older adults living in the community during the COVID-19 lockdown - The case of mauritius. J Aging Stud 2021;57:100932. DOI: 10.1016/j.jaging.2021.100932.

16. Mamun MA. Suicide and Suicidal Behaviors in the Context of COVID-19 Pandemic in Bangladesh: A Systematic Review. Psychol Res Behav Manag 2021;14:695-704. DOI: 10.2147/PRBM.S315760.

17. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. Nature 2021;600(7888):204-207. DOI: 10.1038/d41586-021-03619-8.

Confidential. For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


18. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol 2020;88:106903. (In eng). DOI: 10.1016/j.intimp.2020.106903.

19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep 2021;11(1):8059. (In eng). DOI: 10.1038/s41598-021-86859-y.

20. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother 2020;64(9) (In eng). DOI: 10.1128/aac.01061-20.

21. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med 2021;9(5):498-510. (In eng). DOI: 10.1016/s2213-2600(20)30566-x.

22. Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem 2021;21(10):920-927. (In eng). DOI: 10.2174/1568026621666210429083050.

23. National Institutes of Health. Covid-19 Treatment Guidelines. In: Health NIH, ed.: United States Goverment; 2021.

24. Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol 2018;9:2061. DOI: 10.3389/fimmu.2018.02061.

25. Mazewski C, Perez RE, Fish EN, Platanias LC. Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. Front Immunol 2020;11:606456. DOI: 10.3389/fimmu.2020.606456.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


26. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300. DOI: 10.1016/j.smim.2019.101300.

27. World Health Organization. Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis. . Worl Health Organization.

28. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? Int J Environ Res Public Health 2020;17(11):3997. (In eng). DOI: 10.3390/ijerph17113997.

29. Iturriaga C, Eiffler N, Aniba R, et al. A cluster randomized trial of interferon ss-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). BMC Infect Dis 2021;21(1):814. DOI: 10.1186/s12879-021-06519-4.

30. World Health Organization. Household transmission investigation protocol for 2019-novel coronavirus (COVID-19) infection. Epidemiological protocol. Geneva: World Health Organization, February 28th 2020 2020. (WHO/2019-nCoV/HHtransmission/2020.4) (https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection).

31. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult Scler 2002;8(1):15-8. DOI: 10.1191/1352458502ms771sr.

32. National Health and Medical Research Council. Guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods. Canberra: National Health and Medical Research Council; 2016.

33. Hofmeijer J, Anema PC, van der Tweel I. New algorithm for treatment allocation reduced selection bias and loss of power in small trials. J Clin Epidemiol 2008;61(2):119-24. DOI: 10.1016/j.jclinepi.2007.04.002.

Confidential. For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


34. National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile: National Institute of Statistics (Chile), 2021. (http://ghdx.healthdata.org/record/chile-population-and-housing-census-2017).

35. World Health Organisation. Situation report - 50. Coronavirus disease 2019 (COVID-19) 50. World Health Organisation, 2020. (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports).

36. Yi B, Fen G, Cao D, et al. Epidemiological and clinical characteristics of 214 families with COVID-19 in Wuhan, China. Int J Infect Dis 2021. DOI: 10.1016/j.ijid.2021.02.021.

37. Curmei M, Ilyas A, Evans O, Steinhardt J. Constructing and adjusting estimates for household transmission of SARS-CoV-2 from prior studies, widespread-testing and contact-tracing data. Int J Epidemiol 2021;50(5):1444-1457. DOI: 10.1093/ije/dyab108.

38. Bates DM, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using lme4. Journal of Statistical Software 2015;67(1):1-48. DOI: doi:10.18637/jss.v067.i01.

39. Goodrich B, Gabry J, Ali I, S. B. Bayesian applied regression modeling via Stan. R package version 2.21.1. rstanarm 2020 (https://mc-stan.org/rstanarm.).

40. Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Wolfe R. Joint longitudinal and time-to-event models via Stan. StanCon 2018. 10-12 Jan 2018. Pacific Grove C, USA. https://github.com/stan-dev/stancon_talks/. Joint longitudinal and time-to-event models via Stan. . StanCon 2018. Pacific Grove, CA, USA2018.

41. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol 2015;55(2):179-88. DOI: 10.1002/jcph.390.

Confidential. For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


42. Labhardt ND, Smit M, Petignat I, et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine 2021;42:101188. DOI: 10.1016/j.eclinm.2021.101188.

43. Ben K, Alex M, Mariya K, et al. Nature Portfolio 2022. DOI: 10.21203/rs.3.rs-1121993/v1.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


| | Full study population | | At-risk population | |
|---|---|---|---|---|
| | SOC (n = 565) | IFN (n = 607) | SOC (n = 246) | IFN (n = 293) |
| **Age (years)** | | | | |
| Mean (SD) | 35.0 (19.4) | 33.2 (18.7) | 29.2 (21.0) | 29.0 (20.0) |
| **Sex** | | | | |
| Female, n (%) | 294 (52.0%) | 323 (53.2%) | 133 (54.1%) | 171 (58.4%) |
| Male, n (%) | 271 (48.0%) | 284 (46.8%) | 113 (45.9%) | 122 (41.6%) |
| **Household occupants** | | | | |
| Mean (SD) | 4.10 (1.31) | | 4.28 (1.30) | 4.86 (2.24) |
| **Fully vaccinated for SARS-CoV-2** | | | | |
| No, n (%) | 380 (67.3%) | 438 (72.2%) | 167 (67.9%) | 217 (74.1%) |

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


| | | | | |
|---|---|---|---|---|
| Yes, n (%) | 103 (20.3%) | 169 (27.8%) | 79 (32.1%) | 76 (25.9%) |
| **Cancer** | | | | |
| No, n (%) | 559 (98.9%) | 598 (98.5%) | 245 (99.6%) | 290 (99.0%) |
| Yes, n (%) | 5 (0.9%) | 9 (1.5%) | 0 (0%) | 3 (1.0%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Diabetes** | | | | |
| No, n (%) | 542 (95.9%) | 583 (96.0%) | 238 (96.7%) | 285 (97.3%) |
| Yes, n (%) | 22 (3.9%) | 24 (4.0%) | 7 (2.8%) | 8 (2.7%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Heart disease** | | | | |
| No, n (%) | 533 (94.3%) | 578 (95.2%) | 236 (95.9%) | 281 (95.9%) |
| Yes, n (%) | 31 (5.5%) | 29 (4.8%) | 9 (3.7%) | 12 (4.1%) |

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


| | | | | |
|---|---|---|---|---|
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Asthma** | | | | |
| No, n (%) | 524 (92.7%) | 581 (95.7%) | 230 (93.5%) | 282 (96.2%) |
| Yes , n (%) | 40 (7.1%) | 26 (4.3%) | 15 (6.1%) | 11 (3.8%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Chronic lung disease** | | | | |
| No , n (%) | 564 (99.8%) | 606 (99.8%) | 245 (99.6%) | 292 (99.7%) |
| Yes, n (%) | 0 (0%) | 1 (0.2%) | 0 (0%) | 1 (0.3%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Chronic kidney disease** | | | | |
| No, n (%) | 564 (99.8%) | 604 (99.5%) | 245 (99.6%) | 292 (99.7%) |
| Yes, n (%) | 0 (0%) | 3 (0.5%) | 0 (0%) | 1 (0.3%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


| | | | | |
|---|---|---|---|---|
| **Chronic neurological disease** | | | | |
| No, n (%) | 562 (99.5%) | 602 (99.2%) | 245 (99.6%) | 290 (99.0%) |
| Yes, n (%) | 2 (0.4%) | 5 (0.8%) | 0 (0%) | 3 (1.0%) |
| Missing, n (%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| **Smoker** | | | | |
| No , n (%) | 502 (88.8%) | 519 (85.5%) | 227 (92.3%) | 255 (87.0%) |
| Yes, n (%) | 63 (11.2%) | 88 (14.5%) | 19 (7.7%) | 38 (13.0%) |
| Missing, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |

**Table 1: Full study population demographics at baseline, and at-risk population demographics at baseline.**

Confidential: For Review




Figure 1: CONSORT diagram describing participant screening, enrolment, randomisation, and analysis.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




**Figure 2: Forrest plots describing primary and exploratory study outcomes. (A)** odds ratios for index case populations in Primary Analysis 1 and associated sensitivity analyses, to compare the probability of being SARS-COV-2 negative vs positive on study day 11 in either treatment or standard of care arms. **(B)** odds ratios for household contact populations in Primary Analysis 2 and associated sensitivity analyses, to compare the probability of household contacts being SARS-CoV-2 negative vs positive on study day 11

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

in either treatment or standard of care arms. (C) odds ratios for the exploratory frequentist and Bayesian analysis, to determine if IFN is associated with a reduction in the number of positive COVID-19 tests in household contacts across study period 1 (days 1-11) and study period 2 (days 12-29). Treatment with IFN is associated with a significant reduction in the odds of a positive COVID-19 test for all household contacts compared to standard of care; frequentist analysis ($p = 0.033$; OR = 0.550, 95% CI = 0.364 to 0.989), Bayesian analysis (OR = 0.32, 95% CrI = 0.11 to 0.83). IC-INF = Infected case population (main analysis), IC-ITT = Index case – intention to treat population (sensitivity analysis 7.1.3.2), IC-PP = Index case – per protocol population (sensitivity analysis 7.1.3.3). EHC-ITT = Treatment-eligible household contact – intention to treat population (main analysis), HC = Household contact (eligible + non-eligible contacts) population (sensitivity analysis 7.2.3.2), EHC-PP = Treatment-eligible household contact = per protocol population (sensitivity analysis 7.2.3.3). * $p < 0.05$.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




**Figure 3: $Log_{10}$ viral load in study participants who test positive for COVID-19 after visit 1.**

**(A)** No significant difference in median viral load at each study visit between SOC and IFN arms. **(B)** No significant difference in peak viral load between SOC and IFN arms. SOC = standard of care arm, IFN = interferon arm, cp/mL = copies/mL. n = 57 (IFN) & n = 61 (SOC) participants per group.

Confidential: For Review

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

# Interferon Beta-1α ring prophylaxis to reduce household transmission of SARS-CoV-2

## Supplementary Materials

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**Table of Contents**

List of Study Investigators ..... 4

Supplementary Methods ..... 8

Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2 ..... 8

Viral load calculation ..... 8

Populations used for analyses ..... 9

Bayesian statistical analysis ..... 9

Bayesian model ..... 10

Computation of difference in probability of infection in IFN vs SOC arms ..... 10

Supplementary Results ..... 12

Bayesian analysis of infection reduction ..... 12

Supplementary Figures ..... 13

Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load ..... 13

Supplementary Figure 2 Distribution of the difference in probability of infection between SOC and IFN arms by household size ..... 14

Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms ..... 14

Supplementary Tables ..... 15

Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial ..... 17

Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts. ..... 18

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts ..... 19

Supplementary Table 4: Study withdrawal reasons by treatment arm. ..... 20

Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19. ..... 21

Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis. ..... 23

Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals. ..... 24

Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size ..... 24

Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size ..... 25

Supplementary Table 10: Number of contacts at each household size. ..... 26

Supplementary References ..... 27

Supplementary Appendices ..... 28

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**List of Study Investigators**

**Jose A. Castro-Rodriguez**

Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

**Eleanor N. Fish**

Department of Immunology, University of Toronto, Toronto, Canada

Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

**Tobias Kollman**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Carolina Iturriaga**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

**Yuliya Karpievitch**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Biomedical Sciences, University of Western Australia, Nedlands, Australia

**Casey Shannon**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Robert Balshaw**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Virginia Chen**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Samuel T. Montgomery**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

School of Population Health, Curtin University, Bentley, Australia

**Joseph Ho**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Rad Aniba**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Rym Ben Othman**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Francisca Gidi-Yunge**

School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

**Lucy Hartnell**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Guillermo Pérez-Mateluna**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica De Chile, Santiago, Chile

**Marcela Urzúa**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica De Chile, Santiago, Chile

**Scott Tebbit**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Diego García-Huidobro**

Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Department of Family Medicine and Community Health, University of Minnesota, United States of America

**Cecilia Perret**

Department of Pediatric Infectious Diseases and Immunology , School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

**Arturo Borzutzky**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

**Stephen M. Stick**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Perth Children's Hospital, Nedlands, Australia

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Supplementary Methods

### Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2

RNA extraction and RT-qPCR for SARS-CoV-2 detection was performed at the Infectiology and Molecular Virology Laboratory, Red Salud UC Christus, Santiago, Chile. RNA was extracted in parallel from saliva using the MagBind RNA extraction kit (#GN7101907, Maccura Biotechnology, Rockville, MD, USA) with the Auto-Pure 32A Nucleic Purification System (Maccura Biotechnology, Rockville, MD, USA), and using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Real-time PCR amplification was performed using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) targeting the RNA-dependent RNA polymerase (RdRP) gene, targeting SARS-COV-2, but not other SARS-like viruses (CoVNL63, CoV229E, HKE, OC43, MERS), with a positive control containing three separate diagnostic targets (E gene, N gene, RdRP). The reverse transcription and PCR processes occur in a single step in a real-time thermocycler (Lightcycler 480 II, Roche, Berlin, DE) with an analytical sensitivity of 10.6 copies per reaction. A cycle threshold (Ct) value of ≤ 37 was considered positive for SARS-CoV-2.

### Viral load calculation

The viral load of SARS-CoV-2 detected in saliva was calculated using a standard curve. A commercial SARS-CoV-2 standard (#COV019, Exact Diagnostics, Fort Worth, TX, USA) at a concentration of 200,000 copies per mL (cp/mL) was extracted in triplicate using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Following extraction, serial dilutions (1:10; 200,000cp/mL to 20cp/mL & 1:5; 200,000cp/mL to 64cp/mL) were used in triplicate for reverse transcription and RT-qPCR using the LightMix Modular Wuhan CoV

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) with the Lightcycler 480 II thermocycler (Roche, Berlin, DE), resulting in 9 replicates at each concentration. SARS-CoV-2 was detectable in all nine replicates at 200,000cp/mL, 40,000cp/mL, 20,000cp/mL, 8,000cp/mL, 2000cp/mL, and 1,600cp/mL, and a standard curve was generated using the mean Ct values for these concentrations (Supplementary Figure 1) to calculate SARS-CoV-2 viral load in samples of unknown titre, resulting in a lower limit of quantification of 1,600cp/mL.

**Populations used for analyses**

Participants were excluded for analysis as outlined in the statistical analysis plan, or as outlined in the exploratory analysis (Supplementary Appendix B). Total households and participants excluded and used in each population are described in Supplementary Table 6. Briefly, participants were excluded from the populations used in the primary analyses (IC-INF, IC-ITT, EHC-ITT, HC) if the study visit was not performed, or was performed outside the +/– 1 day window either side of the scheduled visit date (Statistical Analysis Plan 6.5). Participants who didn't complete the full course of the treatment were excluded from the Per Protocol populations used in the primary analyses (IC-PP, EHC-PP). In the exploratory analysis, whole households were excluded if the index case was SARS-CoV-2 negative via salivary PCR at study days 1 & 6, and if there were no SARS-CoV-2 negative eligible or ineligible contacts in the household at study day 1. Participants were then excluded from the exploratory analysis if they were SARS-CoV-2 positive via salivary PCR at study day 1. Participants were further excluded from the Bayesian analysis where household size was greater than 7, as these household sizes were unable to be modelled using Bayesian modelling.

**Bayesian statistical analysis**

Bayesian analysis was included in the original statistical analysis plan. The goal was to test the null hypothesis that treatment of household contacts with IFNβ-1α does not reduce the probability of transmission from an infected index case to household contacts. As outlined in the analysis plan, we

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

used data to develop a data generating process governed by probabilities that a household contact of an index case would test positive to COVID-19, and non-informative prior was used.

**Bayesian model**

A generalized linear model with mixed effects was developed to estimate the probability of infection for each contact. A stan_glmer with binomial logit function from the rstanarm package (1) was run using R (version 4.1.1 ) to obtain Beta coefficients for 4,000 simulated samples to estimate the probability of infection using the following model:

$$pcr \sim (1 \mid index) + vacc + viral + infected + eligible + sex + age + arm$$

where: *pcr*: binary COVID-19 test result, *index*: index case in the household – treated as a random effect, *vacc*: number of vaccinated household members, *viral*: $\log_{10}$ viral load of the index case at the beginning of the period, *infected*: number of COVID-19 positive household members at the beginning of the period, *eligible*: whether the household contact was eligible for treatment, *sex*: sex of the household contact, *age*: age of the household contact, and *arm*: study arm (i.e. SOC/IFN) of the household were the fixed explanatory variables.

The features of the model were the same as the exploratory frequentist analysis, with the exception of adding the treatment period as a feature. Instead, the Bayesian analysis split the data into two periods (Period 1: study days 1–11, Period 2: study days 12–29) with analysis conducted separately. For period 2, COVID-19 positivity at day 11 was used to determine COVID-19 positive household members at the beginning of the period. The population used for analysis was the same as the "At-risk" population used in the exploratory frequentist analysis (Supplementary Table 6), with the additional exclusion of participants in households with a size larger than 8.

**Computation of difference in probability of infection in IFN vs SOC arms**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

In each simulation, we obtained a PCR outcome for each contact from the Bayesian model by applying the posterior_predict function in the rstanarm package to the observed data (1). We further computed the percent of infections in each treatment arm irrespective of household size (Supplementary Table 8) and for each household size (Supplementary Table 9). Furthermore, we computed the difference in probability of infection by subtracting the probability of infection in IFN arm from the probability of infection in SOC arm. As a results, we obtained 4000 differences (irrespective of household size) and 4000 differences for each household size

Significance of the treatment effect was determined by 95% credible interval (CrI) for the treatment Beta coefficient. If 0 was included in the CrI, the effect of treatment group was considered not significant. Average Beta coefficient and odds ratio for the effect of the IFN treatment as compared to SOC were computed in each study period. The average odds ratio of being infected with SARS-CoV-2 on IFN treatment vs. SOC was calculated by exponentiating the values of the average of the coefficients (Supplementary Table 7).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Supplementary Results

### Bayesian analysis of infection reduction

Treatment with IFN had a significant effect in study period 1 as the 95% CrI for treatment coefficient did not include zero (Supplementary Table 7). However, IFN treatment did not have a significant effect in period 2 as the 95% CrI did include zero (Supplementary Table 7).

In study period 1, there was 95% probability of infection reduction between 0.9% to 15.9% due to the IFN treatment, with 8.5% median and mean infection reduction (Supplementary Table 8). In study period 2, there are 95% probability of infection reduction -6.7% to 4.8% due to the IFN treatment, with -9% of median and mean of infection reduction (Supplementary Table 8).

When we stratified the infection reduction by household size, only households' size 3 and 4 in period 1 had a 95% CrI without zero (Supplementary Table 9).

As the distribution of Bayesian estimated differences in probabilities of infection in study period 1 is centred to the right of 0 (Supplementary Figure 3A), IFN treatment had an effect on reducing SARS-CoV-2 transmission within households. However, as the distribution in study period 2 is centred around 0, it suggests IFN has no effect on SARS-CoV-2 transmission within households (Supplementary Figure 3B).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Supplementary Figures




**Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load**. Mean cycle threshold (Ct) values are plotted on the y-axis, and $\log_{10}$ SARS-CoV-2 copies per mL (cp/mL) are plotted on the x-axis. Linear regression resulted in an $R^2$ value of 0.9972, to fit the equation $y = -3.719x + 48.83$.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




**Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms**. **(A)** Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical black line represents zero difference in probability of infection between SOC and IFN arms.




**Supplementary Figure 3 Distribution of the difference in probability of infection between SOC and IFN arms by household size. (A)** Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical dashed black line represents zero difference in probability of infection between SOC and IFN arms.

**Supplementary Tables**

| Primary Objectives | Outcome & Outcome Measure |
|---|---|
| To determine whether IFN β-1α treatment reduces the proportion of infected cases shedding SARS-CoV-2 at day 11 after randomization. | The proportion of index cases shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm |
| To determine whether IFN β-1α treatment reduces the incidence of SARS-CoV-2 transmission from index cases to treatment-eligible household contacts, as measured by any positive upper airway infection evidenced by real-time Polymerase Chain Reaction (RT-PCR), in contacts at day 11 after randomization. | The proportion of household contacts shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm |
| **Secondary Objectives** | **Outcome & Outcome Measure** |
| To determine whether in index cases infected with SARS-CoV-2, IFN β-1α treatment compared with standard of care reduces the duration of SARS-CoV-2 upper airway virus shedding over 28 days following randomization. | Duration (in days) of SARS-CoV-2 measured by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29 |

| | |
|---|---|
| To determine whether IFN β-1α treatment affects the incidence of SARS-CoV-2 upper airway infection or serological conversion by study day 29 in household contacts. | Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 & 11, and seroconversion (IgM) over the study period up to day 29 |
| To determine whether IFN β-1α treatment compared with standard of care reduces the proportion of infected cases that require hospital admission or die due to COVID-19 | The proportion of infected cases in the active arm that are hospitalized or die due to COVID-19, as compared to the proportion in the standard of care arm |
| To determine the safety of IFN β-1α in the treatment and prevention of SARS-CoV-2 infection | Incidence and severity of reported adverse events in the active arm compared to the standard of care arm |
| **Exploratory Objectives** | **Biological samples and associated data will be stored for later access for ethically approved research relevant to the exploratory objectives** |
| Assess the impact of participant demographic and clinical metadata on the viral transmission dynamics and response to IFN β-1α in the household using unbiased systems epidemiology | |
| Assess the impact of host biology on the viral transmission dynamics and response to IFN β-1α in the household using unbiased systems biology | |
| Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β-1α intervention | |

| |
|---|
| Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β-1α intervention |
| Estimate the secondary infection rate, serial interval, incubation period, duration of infectiousness, duration of detected shedding |
| *Individual level:* SARS-CoV-2 shedding as determined by PCR of upper respiratory samples analyzed as a function of time of exposure relative to the start of the intervention |
| *Household/Community level:* While each study arm will be assessed independently of each other as secondary objectives, we will assess the impact of any intervention on the entire household. When demographic and/or biological variables |
| Host immune response (anti SARS-CoV-2 antibodies, blood cytokines and chemokines), as well as blood and nasal mucosal host response (including but not limited to transcriptomics, metabolomics, proteomics, and epigenomics) to IFN β-1α intervention, SARS-CoV-2 infection and their interaction |

**Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial**

| | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Extra Visit – Suspected COVID-19 |
|---|---|---|---|---|---|---|---|
| **Study Day** | **1**<br>**Dose 1** | **6**<br>**Dose 2** | **11**<br>**Dose 3** | **16** | **21** | **29** | |
| **Blood Samples** | | | | | | | |
| Complete Blood count/ ESR | X | | | | | X | X |
| SARS-CoV-2 antibodies (IgGAM) | X | | | | | X | |
| Study sample 1 | X | X | X | | | X | X |
| Study sample 2 | X | X | X | | | X | X |
| Study sample 3 | X | X | X | | | X | X |
| **Airway samples** | | | | | | | |
| Nasal brush | X | | | | | | |
| Nasal lining fluid | X | X | X | | | | |
| Airway Swab for COVID-19 diagnosis | | | | | | | X |
| **Saliva Samples** | | | | | | | |
| Saliva | X | X | X | X | X | X | X |

**Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.**

| | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Extra Visit – Suspected COVID-19 |
|---|---|---|---|---|---|---|---|
| **Study Day** | **1**<br>**Dose 1** | **6**<br>**Dose 2** | **11**<br>**Dose 3** | **16** | **21** | **29** | |
| **Blood Samples** | | | | | | | |
| Complete Blood count/ ESR | | | | | | | X |
| SARS-CoV-2 antibodies (IgGAM) | | | | | | X | |
| Study sample 1 | | | | | | X | X |
| Study sample 2 | | | | | | X | X |
| Study sample 3 | | | | | | X | X |
| **Airway samples** | | | | | | | |
| Nasal brush | X | | | | | | |
| Nasal lining fluid | X | X | X | | | | |
| Airway Swab for COVID-19 diagnosis | | | | | | | X |
| **Saliva Samples** | | | | | | | |
| Saliva | X | X | X | X | X | X | X |

**Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.**

| Interferon arm | | | | | | | | | | Standard of Care arm | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **Days since enrolment** | | | | | | | | | | **Days since enrolment** | | | | | | | | |
| **Withdrawal reason** | **3** | **4** | **5** | **10** | **11** | **14** | **15** | **21** | **28** | **Withdrawal reason** | **3** | **4** | **5** | **10** | **11** | **14** | **15** | **25** | **28** |
| Family withdrew | 0 | 0 | 5 | 0 | 0 | 2 | 0 | 0 | 0 | Family withdrew | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interpersonal problems | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | Interpersonal problems | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lack of time | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Lack of time | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Parental decision | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | Parental decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poor health | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | Poor health | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sample collection problems | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Sample collection problems | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Side effects of drug | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | Side effects of drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Uninterested | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | Uninterested | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unspecified | 4 | 3 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | Unspecified | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 5 | 0 |
| Work commitments | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | Work commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

**Supplementary Table 4: Study withdrawal reasons by treatment arm.**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

| Reasons for exclusion from ConCorD-19 during screening | Participants (n) |
|---|---|
| Unable to be contacted | 736 |
| Days of symptoms > 5 | 777 |
| Asymptomatic | 306 |
| Isolating from household contacts | 219 |
| Hospitalized | 177 |
| Confirmation of COVID-19 took longer than 72 hours | 35 |
| Deceased | 2 |
| Ineligible medical condition or treatment | 67 |
| Less than 18 years old | 54 |
| Pregnant, or plans on becoming pregnant | 32 |
| Previously infected with COVID-19 | 36 |
| Greater than 80 years old | 3 |
| All eligible household contacts currently infected | 514 |
| Does not live with eligible household contact | 412 |
| Not the first infection in the household | 392 |
| Does not live in the Santiago metropolitan area | 20 |
| **Reasons for not participating in ConCorD-19** | |
| Index case declined | 835 |
| Eligible household contact declined | 196 |
| **Total** | **4813** |

**Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.**

| Analyses outlined in SAP | | Exclusions | | Participants (n) included for analyses | | |
|---|---|---|---|---|---|---|
| **Analysis** | **Population** | **Reason** | **Participants (n)** | | **IFN** | **SOC** |
| | Full study population | | | **IC** | 172 | 169 |
| | | | | **EHC** | 177 | 165 |
| | | | | **CP-HC** | 80 | 81 |
| | | | | **IHC** | 178 | 150 |
| Primary 1 - Main | IC-INF at day 11 | No visit | 22 | **IC** | 159 | 164 |
| | | Visit outside window | 3 | **CP-HC** | 69 | 76 |
| Primary 1 – Sensitivity 1 | IC-ITT at day 11 | No visit | 12 | **IC** | 159 | 164 |
| | | Visit outside window | 2 | | | |
| Primary 1 – Sensitivity 2 | IC-PP at day 11 | No visit or protocol deviation | 26 | **IC** | 146 | 164 |
| | | Visit outside window | 1 | | | |
| Primary 2 – Main | EHC-ITT at day 11 | No visit | 20 | **EHC** | 166 | 156 |
| Primary 2 – Sensitivity 1 | HC at day 11 | No visit | 37 | **EHC** | 166 | 156 |
| | | | | **IHC** | 168 | 143 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Primary 2 – Sensitivity 2 | EHC-PP at day 11 | No visit or protocol deviation | | 30 | **EHC** | 156 | 156 |
| **Exploratory Analyses** | | **Exclusions** | | | | | |
| **Analysis** | **Population** | **Reason** | **Households (n)** | **Participants (n)** | | | |
| Frequentist | Household contacts, COVID-19 negative at study day 1 | COVID-negative index case | 33 | | **EHC** | 164 | 142 |
| | | No household contacts at risk | 49 | | | | |
| | | Household contact COVID positive | | 43 | **IHC** | 129 | 104 |
| Bayesian | Frequentist population, household size ≤ 7 | Household size > 7 | 5 | 61 | **EHC** | 152 | 139 |
| | | | | | **IHC** | 113 | 104 |

**Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis.** IC: index case, EHC: Treatment eligible household contacts, CP-HC: COVID-19 positive household contacts, IHC: Treatment ineligible household contacts, IC-INF: IC & CP-HC, IC-ITT: Index case – intention to treat population, IC-PP: Index case – per protocol population, EHC-ITT: Treatment eligible household contacts – intention to treat population, HC: EHC and IHC, EHC-PP: Treatment eligible household contact – per protocol population.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

| Coefficient for treatment with IFN | | | 95% Credible Intervals | |
|---|---|---|---|---|
| Study period | Mean | Standard Deviation | Lower limit (2.5%) | Upper limit (97.5%) |
| 1 | -1.17 | 0.52 | -2.23 | -0.19 |
| 2 | 0.27 | 0.55 | -0.80 | 1.36 |

| Odds ratio for treatment with IFN | | | 95% Credible Intervals | |
|---|---|---|---|---|
| Study period | Mean | Standard Deviation | Lower limit (2.5%) | Upper limit (97.5%) |
| 1 | 0.32 | 1.68 | 0.11 | 0.83 |
| 2 | 1.31 | 1.73 | 0.45 | 3.90 |

**Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.**

| Study period | 2.5% | 25% | 50% | Mean | 75% | 97.5% |
|---|---|---|---|---|---|---|
| 1 | 0.009 | 0.059 | 0.085 | 0.085 | 0.110 | 0.159 |
| 2 | -0.067 | -0.028 | -0.009 | -0.009 | 0.010 | 0.048 |

**Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size**. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

| Study period | Household size | 2.5% | 25% | 50% | Mean | 75% | 97.5% |
|---|---|---|---|---|---|---|---|
| 1 | 2 | -0.143 | 0.000 | 0.286 | 0.053 | 0.143 | 0.286 |
| 1 | 3 | 0.000 | 0.092 | 0.276 | 0.139 | 0.184 | 0.276 |
| 1 | 4 | 0.003 | 0.087 | 0.249 | 0.128 | 0.170 | 0.249 |

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 1 | 5 | -0.146 | -0.046 | 0.158 | 0.005 | 0.058 | 0.158 |
| 1 | 6 | -0.120 | 0.030 | 0.326 | 0.103 | 0.189 | 0.326 |
| 1 | 7 | -0.231 | -0.077 | 0.308 | 0.024 | 0.077 | 0.308 |
| 2 | 2 | -0.118 | -0.059 | 0.075 | -0.008 | 0.000 | 0.075 |
| 2 | 3 | -0.085 | -0.021 | 0.090 | 0.001 | 0.028 | 0.090 |
| 2 | 4 | -0.130 | -0.068 | 0.059 | -0.037 | -0.006 | 0.059 |
| 2 | 5 | -0.128 | -0.052 | 0.103 | -0.013 | 0.027 | 0.103 |
| 2 | 6 | -0.129 | -0.015 | 0.254 | 0.059 | 0.117 | 0.254 |
| 2 | 7 | -0.154 | 0.000 | 0.154 | 0.016 | 0.077 | 0.154 |

**Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size.** Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

| Household size | Number of households | Eligible Contacts | Ineligible Contacts |
|---|---|---|---|
| 2 | 42 | 42 | 0 |
| 3 | 61 | 64 | 27 |
| 4 | 80 | 84 | 89 |
| 5 | 46 | 58 | 59 |
| 6 | 19 | 29 | 30 |
| 7 | 6 | 14 | 12 |

**Supplementary Table 10: Number of contacts at each household size.**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

# Supplementary References

1. Goodrich B GJ, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3 ed2022.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.13.22276369; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

# Supplementary Appendices